Foralumab is the first intranasal immune modulator in clinical trials for patients with Multiple System AtrophyBOSTON, May 14 ...
Tiziana Life Sciences reported encouraging brain inflammation findings in its MSA study, strengthening attention on ...
Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports ...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Publication of a peer-reviewed study from Alterity Therapeutic’s bioMUSE study shows an advanced MRI imaging method detects ...
Compared with placebo, ATH434 demonstrated a statistically significant 48% slowing of clinical progression (based on UMSARS score) at the 50mg dose at week 52. The Food and Drug Administration (FDA) ...
NEWTON, Mass.--(BUSINESS WIRE)--Inflammasome Therapeutics (https://www.inflam.com/), a clinical-stage biotech company developing novel, first-in-class dual ...
MedPage Today on MSN
Is pure autonomic failure a warning sign for Parkinson's? What a new study shows.
High conversion rates to Parkinson's, dementia with Lewy bodies, or multiple system atroph ...
Foralumab is the first intranasal immune modulator in clinical trials for patients with Multiple System AtrophyBOSTON, May 14 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results